血管内皮生长因子基因多态性与肾细胞癌相关性的系统评价与Meta分析  

Vascular Endothelial Growth Factor Gene Polymorphisms and Renal cell Carcinoma: A Systematic Review and Meta-analysis

作　　者：周华[1] 赵静[2] 常双[2] 涂明利[1] 

机构地区：[1]湖北医药学院附属随州医院医务科,湖北随州441300 [2]湖北医药学院附属太和医院肿瘤科,湖北十堰442000

出　　处：《湖北医药学院学报》2014年第4期370-378,共9页Journal of Hubei University of Medicine

基　　金：湖北省自然科学基金资助课题(2013CFB468)

摘　　要：目的:采用Meta分析的方法评价血管内皮生长因子(VEGF)基因多态性与肾细胞癌(RCC)的发病风险关系。方法:检索PubMed数据库中公开发表的关于VEGF基因多态性与RCC发病风险关系的病例-对照研究,检索截止时间为2013年10月。进行文献筛选、数据提取后,采用RevMan 5.2软件进行Meta分析。结果:最终纳入5篇病例-对照研究,均为英文文献,包括8个单核苷酸多态性。Meta分析结果显示:VEGF基因936C/T、1612G/A、-1154G/A、-2549I/D、-460T/C和405G/C多态性与RCC发病风险无关;对于702C/T多态性,在研究中未发现该位点突变基因;-2578C/A多态性可能增加RCC发病风险。结论:当前证据表明VEGF基因-2578C/A多态性可能与RCC相关。受到本研究局限性的限制,仍需进一步开展高质量的病例-对照研究来加以验证该结论。Objective To evaluate the association between vascular endothelial growth factor（ VEGF） gene polymorphism and the risk of renal cell carcinoma（ RCC） by using a systematic review and meta-analysis. Methods The relevant published case-control studies until October 2013 were searched in PubMed database. After data extraction and quality assessment,the meta-analysis was performed by using RevMan 5. 2 software. Results Finally 5 case-control studies involving eight polymorphisms published in English was identified from PubMed. The results of meta-analysis indicated that the VEGF 936 C /T,1612 G / A,-1154 G /A,-2549 I /D,-460 T /C and 405 G /C gene polymorphisms were not associated with the risk of RCC.There was no polymorphism in 702 C /T and RCC,while the-2578 C /A gene polymorphism may be associated with the increasing risk of RCC. Conclusion Current evidence indicated that the VEGF-2578 C /A polymorphism might be associated with RCC risk. However,due to the limitation of the present study,further high quality case-control studies are warranted to confirm these findings.

关 键 词：血管内皮生长因子 多态性 肾细胞癌 META分析 系统评价 病例-对照研究 

分 类 号：R737.11[医药卫生—肿瘤]